How Common Is BV? Prevalence, Risks, and Recurrence

Bacterial vaginosis affects roughly one in four women of reproductive age worldwide, making it the most common vaginal condition in that population. A large systematic review and meta-analysis estimated global prevalence between 23% and 29% depending on region, with North America sitting near 27%.¹ Despite those numbers, most people with BV have no idea they have it, and the condition’s tendency to return after treatment has frustrated researchers and patients for decades.

How Many People Actually Have BV

In the United States, a nationally representative study using data from the early 2000s found that about 29% of women aged 14 to 49 had BV at the time they were tested, which translated to an estimated 21 million affected women.² Those numbers are strikingly high for a condition many people have never heard of, or confuse with a yeast infection. Globally, the picture is similar. Regional estimates from a meta-analysis range from about 23% in Europe and Central Asia to 29% in South Asia, with sub-Saharan Africa, the Middle East, and the Americas falling in between.¹

Those prevalence figures come from studies that tested women regardless of whether they reported symptoms. And that distinction matters a lot, because earlier epidemiological work found that prevalence ranged from as low as 5% in women without any symptoms to around 25% in those who visited a clinic with gynecologic complaints.³ The gap between these numbers and the 29% figure is explained by the fact that most BV goes unnoticed. In the U.S. prevalence study, only about 16% of women who tested positive for BV reported vaginal symptoms.² The other 84% had no complaints at all. BV is largely a silent condition.

What Is Actually Happening in the Vaginal Microbiome

A healthy vagina is dominated by Lactobacillus bacteria, which produce acids and antimicrobial compounds that keep other microbes in check.⁴ BV develops when those Lactobacillus populations drop sharply and get replaced by a surge of anaerobic bacteria. The result is typically a rise in vaginal pH above its normal acidic range, often accompanied by a thin grayish discharge and a fishy odor, though as noted above, many people experience no noticeable change at all.

One bacterium in particular, Gardnerella vaginalis, plays a central role. Gardnerella tends to form sticky biofilms that adhere tightly to the vaginal lining, and research has found these biofilms are heavily protein-based.⁵ BV biofilms are not just Gardnerella acting alone. They are polymicrobial communities, with other species like Enterococcus and Actinomyces sometimes enhancing Gardnerella’s ability to cause harm.⁶ This biofilm structure is a major reason BV is so hard to eliminate for good: antibiotics can kill free-floating bacteria effectively, but the biofilm shields the organisms living inside it. In lab tests, the concentration of metronidazole needed to eradicate Gardnerella biofilms was far higher than the dose needed to kill the bacteria outside a biofilm.⁷

Who Is Most at Risk

BV can affect anyone with a vagina, but several factors shift the odds. Sexual behavior is one of the strongest and most consistently observed. A systematic review and meta-analysis of observational data found that new or multiple male sexual partners raised BV risk by about 60%, while having any female sexual partners roughly doubled the risk. Condom use, by contrast, was linked to a modest protective effect.⁸ Having a partner who is sexually involved with other people also appears to raise the likelihood of BV.⁹

Vaginal douching has long been suspected as a contributor, and longitudinal data backs this up. Women who douched regularly had roughly a 20% higher risk of developing BV compared with women who did not douche, and those who had douched within the past week faced about twice the odds of having BV.¹⁰¹¹ Whether the douching was done for hygiene or in response to symptoms didn’t matter much; both reasons were linked to disrupted vaginal flora.

Hormonal fluctuations also play a role. Studies tracking the vaginal microbiome across the menstrual cycle have found that Lactobacillus levels dip during menstruation, when estrogen is at its lowest point. In one study, nearly 60% of participants had a dysbiotic vaginal microbiome during their period, compared with about 30% during other phases of the cycle.¹² Daily tracking confirmed that microbial diversity rises and Lactobacillus abundance falls during menses, with estrogen levels appearing to be a key regulator.¹³ This helps explain why hormonal contraception is sometimes associated with lower BV recurrence: steady estrogen exposure keeps Lactobacillus populations more stable.

Racial Disparities That Risk Factors Don’t Fully Explain

BV prevalence is not evenly distributed across racial groups. In U.S. data, Black women consistently test positive for BV at higher rates than white women. A natural question is whether this reflects differences in known risk factors like douching, smoking, or sexual behavior. Researchers examined exactly that and found that after adjusting for every demographic and lifestyle factor they could measure, Black women still had more than twice the odds of BV or BV-related vaginal flora compared with white women.¹⁴ The disparity persisted, suggesting that unmeasured factors are at work. These might include differences in baseline vaginal microbiome composition, genetic variation in immune responses, or structural factors like differential access to healthcare. The honest answer is that the scientific community does not yet fully understand why the disparity exists.

Health Consequences Beyond Discomfort

BV’s high rate of asymptomatic cases sometimes leads people to assume it’s harmless. It isn’t. The condition is linked to a range of serious reproductive and infectious health outcomes.

Preterm Birth

For pregnant women, BV roughly doubles the risk of delivering prematurely. A meta-analysis found an overall odds ratio of about 1.8 for preterm birth among women with BV.¹⁵ Earlier work published in the New England Journal of Medicine similarly found that BV was associated with preterm delivery of a low-birth-weight infant even after accounting for other risk factors.¹⁶ More recent prospective data suggests BV’s effect on preterm birth may be amplified when it occurs alongside other infections like chlamydia, with coinfected women seeing even higher rates of premature delivery.¹⁷

HIV and Other Infections

BV is associated with a roughly 60% increase in the risk of acquiring HIV. A meta-analysis of prospective studies confirmed this elevated risk.¹⁸ The mechanism involves disrupted mucosal barriers and shifts in local immune function. BV tends to increase inflammatory markers in the vaginal environment, including certain cytokines, while decreasing protective antimicrobial peptides.¹⁹ That combination of more inflammation and weaker antimicrobial defenses makes the vaginal lining more vulnerable to sexually transmitted pathogens.²⁰

Fertility and IVF Outcomes

BV has been linked to infertility, chronic inflammation of the uterine lining, and pelvic inflammatory disease (PID), all of which can impair the ability to conceive.²¹ The BV-PID connection deserves a caveat, though. One large prospective study of high-risk women found no significant increase in PID risk from BV alone after adjusting for confounders.²² However, when specific BV-associated bacteria were measured in higher concentrations, and when chlamydia was also present, the risk of PID within the following three months was elevated.²³ The picture that’s emerging is that BV may not cause PID directly in all cases, but the bacterial shifts it involves can set the stage, especially when other pathogens are in the mix.

For women undergoing IVF, the microbiome matters too. A systematic review and meta-analysis found that vaginal dysbiosis was associated with about a 50% higher risk of early pregnancy loss and a lower clinical pregnancy rate per embryo transfer.²⁴ Another meta-analysis found a significant increase in early miscarriage among IVF patients with BV, though overall live-birth rates were not significantly affected.²⁵ One small prospective study was more alarming: only about 9% of women with abnormal vaginal microbiota achieved a clinical pregnancy, versus a much higher rate in women with normal flora.²⁶ That study was small, so the exact numbers should be taken with caution, but the direction of the finding is consistent with the larger meta-analyses.

Treatment Works Well at First, Then Falls Apart

The standard treatments for BV are oral metronidazole or clindamycin, given either by mouth or applied vaginally. Head-to-head comparisons have found no significant difference in effectiveness between these options, with initial cure rates in the range of 75% to 86%.²⁷ Short-term cure rates near 80% after a seven-day course of oral metronidazole are typical.²⁸

The problem is what comes after. Within 12 months, about 58% of women experience a full recurrence of BV, and if you include milder disruptions to vaginal flora, the figure climbs to about 69%.²⁹ That same study found that a prior history of BV, having a regular sexual partner, and having female sexual partners were all independently associated with recurrence, while hormonal contraception use was linked to a lower chance of BV returning.²⁹ The biofilm structure described earlier is likely a major contributor to these failures. Antibiotics may clear most of the bacteria, but the remaining biofilm scaffold can serve as a platform for regrowth once treatment stops.

Does Treating Male Partners Help

Given the evidence linking sexual activity to BV risk and recurrence, a logical question is whether treating a woman’s male sexual partner could break the cycle. There is evidence that BV-associated bacteria can be exchanged between sexual partners.³⁰ A high-profile randomized trial (the StepUpRCT) tested combined oral and topical antibiotic treatment for male partners and found a meaningful reduction in BV recurrence, attracting considerable attention. However, a subsequent meta-analysis pooling all available randomized trials found no overall significant benefit from male partner treatment, with a pooled risk ratio very close to 1.³¹ When the StepUpRCT (the only trial that used both oral and topical therapy for men) was excluded from the analysis, the remaining trials showed no effect at all. This suggests that the specific regimen used may matter, but the idea that routinely treating male partners will solve BV recurrence is not supported by the broader evidence yet. More trials testing combination approaches are needed before clinical guidelines change.

How BV Is Diagnosed

Two methods dominate clinical practice. The first, known as Amsel criteria, is a bedside approach that looks for at least three of four signs: a thin, homogeneous vaginal discharge; vaginal pH above 4.5; a fishy smell when the discharge is mixed with potassium hydroxide; and the presence of “clue cells” (vaginal cells coated in bacteria) under a microscope. The second method, the Nugent score, involves examining a Gram-stained vaginal smear under a microscope and grading the ratio of Lactobacillus to BV-associated bacteria on a 0-to-10 scale. Nugent scoring is considered the gold standard in research settings.

In practice, Amsel criteria can miss a lot of cases. One comparative study found Amsel criteria had only 50% sensitivity against the Nugent gold standard, meaning about half of women with BV on Nugent scoring were missed by the bedside test.³² Among individual Amsel criteria, clue cells had the highest specificity (100% in that study), but the whiff test had quite low sensitivity. Another study among HIV-positive women found Amsel criteria poorly predictive of BV overall.³³

Molecular diagnostics are starting to gain ground. Quantitative PCR tests that measure concentrations of Gardnerella and other BV-associated species have shown excellent agreement with the Nugent score, achieving 100% sensitivity and 93% specificity in one evaluation.³⁴ These tests are more expensive and less widely available, but they could help catch the many asymptomatic cases that Amsel criteria miss and that Nugent scoring captures only in research labs.

Probiotics and Emerging Therapies

Given BV’s frustrating recurrence rate, researchers have been looking at ways to rebuild the vaginal microbiome after antibiotic treatment. Probiotics containing specific Lactobacillus strains are the most studied approach. A randomized placebo-controlled trial using vaginal capsules of Lactobacillus crispatus after standard antibiotic treatment found that recurrence dropped from about 41% in the placebo group to about 21% in the probiotic group over four menstrual cycles, and the time until recurrence was about 28% longer in the probiotic group.³⁵ Another randomized trial found that both oral and vaginal formulations of L. crispatus improved BV symptoms, reduced Nugent scores, and increased vaginal Lactobacillus counts.³⁶

A systematic review examining multiple probiotic strains and regimens found that Lactobacillus rhamnosus at high doses for 10 days showed the strongest effect on improving vaginal pH, microbiota composition, and reducing recurrence, though L. crispatus, L. plantarum, and L. acidophilus also demonstrated potential across various studies.³⁷ None of this means you can grab any probiotic off a shelf and expect results. The specific strains, dosing, and route of administration all seem to matter, and the evidence is still too thin to support firm clinical guidelines for probiotic use in BV prevention.

On a more experimental front, researchers are exploring targeted biological agents that can attack Gardnerella biofilms directly. One approach uses an enzyme derived from a different bacterial species (Pseudomonas aeruginosa) that disrupts the protein-heavy Gardnerella biofilm matrix and then kills the exposed bacteria.⁵ Another preclinical project is developing a Gardnerella-specific endolysin, a virus-derived enzyme that targets Gardnerella cells with high precision. Early lab data showed it eliminated Gardnerella from biofilms effectively and appeared resistant to the kind of bacterial adaptation that weakens conventional antibiotics over time.³⁸ Both approaches are still in early stages, but they represent a shift in thinking: instead of flooding the vagina with broad-spectrum antibiotics and hoping the right bacteria grow back, the goal is to dismantle the specific structure that allows BV to persist and recur.